Business Wire

ENGELHART-COMMODITIES

26.8.2024 09:01:29 CEST | Business Wire | Press release

Share
Engelhart Commodities Trading Partners Completes the Acquisition of Trailstone Group

Engelhart Commodities Trading Partners, a global commodities trading business, is delighted to announce the successful completion of its acquisition of Trailstone, a global energy and technology company, from Riverstone.

The acquisition will combine the resources and expertise of two successful businesses and enable them to leverage their joint capabilities to enhance trading performance, grow their customer business and play a leading role in decarbonizing the world’s energy matrix.

Trailstone is a global leader in providing risk management and optimization services to the owners and operators of renewable power generation assets. It uses its expertise, analytics, and proprietary software to help manage the intermittency of renewable power generation. Trailstone is also active in trading power, natural gas, and environmental products across North America, Europe, and Asia.

Trailstone has also built a successful physical natural gas client business in North America and Mexico. This business provides storage, transportation, and supply capabilities to serve its customers' growing optimization and risk management requirements.

The acquisition is a pivotal part of Engelhart’s strategic plan to strengthen its global power and gas trading platform and technological capabilities and generate value through active participation in the clean energy transition.

Huw Jenkins, CEO, Engelhart, says:

“We are delighted to complete our acquisition of Trailstone, which is the start of an exciting new chapter for our combined business. By integrating our advanced quantitative modelling and weather forecasting capabilities with Trailstone’s strong presence in the renewable power and gas markets, we create a powerful force for growing our trading activities across the commodities complex. The shift from hydrocarbons to renewable energy is inevitable and transformative, and this acquisition means we will be at the vanguard of that transition.”

John Redpath, Deputy CEO, Engelhart, says:

“I want to thank our partners, investors, customers, and all the employees at both Trailstone and Engelhart for their patience and hard work in helping us close this deal. Our vision for the combined business is to create the commodity merchant of the future. Technology will be central to the energy transition, and by integrating our trading expertise and risk management with Engelhart’s capabilities, we are perfectly positioned to manage renewable power generation and facilitate carbon reduction. This merger represents an exciting milestone, and we are ready to build our combined company together.”

FOR EDITORS

  • Engelhart is an international commodity trading company founded in 2013. It has ~ 170 staff across offices in London, Geneva, Houston, Stamford, Singapore, Shanghai, and Beijing.
  • Engelhart trades power, gas, and oil but is also active in agricultural/soft commodities, freight, and the innovative area of ‘risk premia’.
  • Engelhart is owned by the same partner group that controls BTG Pactual, the largest investment bank in Latin America.
  • Trailstone is a global energy and technology trading company focusing on renewables.
  • It was founded in 2013, and has ~275 staff across offices in Europe, North America, and Japan, with its primary offices in London, Austin, and Berlin.
  • Engelhart has acquired Trailstone from Riverstone LLC, the private equity fund that was their primary shareholder.

  • Huw Jenkins will be the CEO of the new combined business; John Redpath will be Deputy CEO.
  • The new entity will be called “Engelhart” or “Engelhart Commodities Trading Partners”.
  • Latham & Watkins acted as legal advisers to Riverstone and Trailstone.
  • Skadden, Arps, Slate, Meagher & Flom acted as legal adviser to Engelhart Commodities Trading Partners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240826978018/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye